Skip to content

Industry Workshops

All Industry Workshops take place on Wednesday,
October 30, 2019 from 12:00pm – 1:00pm.

AMCP Industry Workshops may include preapproved information exchange content. Subject to federal laws and regulations, attendance at PIE sessions is restricted to payors, formulary committee, or other similar entity representatives with knowledge and expertise in the area of health care economic analysis, carrying out responsibilities for the selection of drugs for coverage or reimbursement. For more information, visit our website.

Early Treatment for Presymptomatic Patients with Spinal Muscular Atrophy

12:00pm-1:00pm / National Harbor Room 2-3
Provided by Biogen

Description: Spinal muscular atrophy (SMA) is a rare, progressive neuromuscular disease primarily diagnosed in infants and children. In addition, SMA is a leading cause of infant mortality. Infants who are diagnosed with SMA Type 1, (infantile onset), typically experience symptoms between birth and age 6 months. Because SMA is definitively diagnosed through genetic testing, the early identification of infants who have the disease is important to determine a care and treatment plan. This session will provide an overview of SMA, with a focus on newborn screening and benefits of early treatment in the presymptomatic stage. This program is open only to representatives of payers, formulary committees, or other similar entities who have responsibility for the selection of drugs for coverage or reimbursement.

Speaker: Diana Patricia Castro, MD, Pediatric Neurology and Neuromuscular Medicine, Children’s Health, Dallas, Texas

Nonradiographic Axial Spondyloarthritis (nr-axSpA) – Inadequately Diagnosed and Inadequately Treated

12:00pm-1:00pm / National Harbor Room 4-5
Provided by UCB, Inc.

Description: Nonradiographic Axial Spondyloarthritis comprises a distinct set of patients within the SpA family of chronic inflammatory diseases and predominantly affects the axial skeleton and is a significant burden to patients. Approximately 5% of chronic back pain cases in the US are caused by nr-axSpA or Ankylosing Spondylitis. Nr-axSpA is associated with severe symptoms, impaired quality of life, and decreased work productivity. Prior to 2019, there were no FDA approved therapies for nr-axSpA. During this session we will discuss the impact this disease has on patients and solutions that are currently available. The expert representative(s) will present the latest clinical and cost-effectiveness information, patient experience and overview of investigational and approved treatments.

Speaker: Jeffrey L. Stark, MD. FACR, Head of Rheumatology Medical Affairs, UCB, Inc.

Evolving Management of Dyslipidemia: A PCSK9i Update

12:00pm-1:00pm / National Harbor Room 10-11
Provided by Sanofi

Description: Two Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) have been approved since 2015 and recent data has led the FDA to approve new indications for PCSK9i. In addition, 12 professional organizations (including AHA, ACC, NLA, ESC, and AMCP) supported the revised Guideline on the Management of Blood Cholesterol for statins and non-statins therapy in appropriate risk patients not at LDL-C targets. For the first time, this clinical guideline included cost-effectiveness associated with the use of the PCSK9i class. As PCSK9i initially were predicted by payers to have a substantial budget impact, various utilization management (UM) criteria were developed for appropriate use and evidence based patient selection. Recent research has demonstrated that restrictions to a PCSK9i for appropriate patients may lead to unintended suboptimal care. We will review guidelines for the management of dyslipidemia, changes in the healthcare landscape, policy impacting patient access and opportunities associated with the use of PCSK9i and their impact on patient outcomes.

Speaker:Mark J. Cziraky, PharmD, CLS, FAHA, FNLA
Vice President, Research, HealthCore

Combining Prescription and Qualitative Member Data to Address Medication Use and Social Determinants of Health in Medically Complex and Vulnerable Seniors

12:00pm-1:00pm / National Harbor Room 12-13
Provided by RxAnte

Description: This workshop focuses on developing a better understanding of the potential value inherent in combining structured medication use data with qualitative information collected during live medication reviews with medically complex and vulnerable Medicare members. When combined, these data assets can create a more informed and actionable picture that enables health plans to better address both medication use barriers and other social determinants of health that impact member health, satisfaction, and total costs of care. Kerri Petrin, VP of Strategy and Business Development at RxAnte, will facilitate an interactive discussion on what early analyses of these data may indicate about Medicare populations, and how best managed care organizations might package and deploy this information to design effective clinical and SDOH-focused quality improvement programs.

Speaker: Kerri Petrin, MPH, VP, Strategy and Business Development, RxAnte and Kevin Ridderhoff, GM of Mosaic Pharmacy Service, RxAnte